<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hyoscyamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hyoscyamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hyoscyamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10749" href="/d/html/10749.html" rel="external">see "Hyoscyamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13369" href="/d/html/13369.html" rel="external">see "Hyoscyamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181212"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anaspaz;</li>
<li>Ed-Spaz [DSC];</li>
<li>Hyosyne;</li>
<li>Levbid;</li>
<li>Levsin;</li>
<li>Levsin/SL;</li>
<li>NuLev;</li>
<li>Oscimin;</li>
<li>Oscimin SR [DSC];</li>
<li>Symax Duotab [DSC];</li>
<li>Symax-SL [DSC];</li>
<li>Symax-SR [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F181239"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F181216"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="601bab7e-831f-4c31-9a21-5a4740b1afc7">Gastrointestinal disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal disorders:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> American College of Gastroenterology guidelines recommend against use of antispasmodics such as hyoscyamine for the treatment of <b>global symptoms</b> of irritable bowel syndrome (IBS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591'])">Ref</a></span>); however, some experts consider as-needed use beneficial for relief of abdominal pain associated with IBS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: 0.125 to 0.25 mg every 4 to 8 hours or as needed; maximum: 1.5 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: 0.375 to 0.75 mg every 12 hours or 0.375 mg every 8 hours; maximum: 1.5 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV, SUBQ:</b> 0.25 to 0.5 mg; may repeat as needed up to 4 times daily, at 4-hour intervals.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990813"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling, use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988018"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F181217"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F181229"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13369" href="/d/html/13369.html" rel="external">see "Hyoscyamine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oral dosage forms (drops and elixirs) are different (ie, 0.125 mg/mL [drops] and 0.125 mg/5 mL [solution]); precaution should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented with corresponding product formulation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1aed3f9-2979-4910-a5a6-00084cb3d278">Gastrointestinal and urinary systemic spasms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal and urinary systemic spasms (including infant colic, biliary and renal colic):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: Oral: Drops (eg, Hyosyne [0.125 mg/<b>mL</b>]): Do not exceed 6 doses in 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">3.4 to &lt;5 kg: 0.01375 mg (0.11 mL or 4 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.0825 mg (0.66 mL or 24 <b>drops</b>)/day</p>
<p style="text-indent:-2em;margin-left:6em;">5 to &lt;7 kg: 0.0175 mg (0.14 mL or 5 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.105 mg (0.84 mL or 30 <b>drops</b>)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">7 to &lt;10 kg: 0.02 mg (0.16 mL or 6 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.12 mg (0.96 mL or 36 <b>drops</b>)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">≥10 kg: 0.0275 mg (0.22 mL or 8 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.165 mg (1.32 mL or 48 <b>drops</b>)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;12 years: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Drops (eg, Hyosyne [0.125 mg/<b>mL</b>]): 0.03125 mg (0.25 mL) to 0.125 mg (1 mL) every 4 hours or as needed; maximum daily dose: 0.75 mg (6 mL)/<b>day</b>; do not exceed 6 doses in 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Elixir (eg, Hyosyne [0.125 mg/<b>5 mL</b>]): Do not exceed 6 doses in 24 hours:</p>
<p style="text-indent:-2em;margin-left:8em;">10 to &lt;20 kg: 0.03125 mg (1.25 mL) every 4 hours or as needed; maximum daily dose: 0.1875 mg (7.5 mL)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">20 to &lt;40 kg: 0.0625 mg (2.5 mL) every 4 hours or as needed; maximum daily dose: 0.375 mg (15 mL)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">40 to &lt;50 kg: 0.09375 mg (3.75 mL) every 4 hours or as needed; maximum daily dose: 0.5625 mg (22.5 mL)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: 0.125 mg (5 mL) every 4 hours or as needed; maximum daily dose: 0.75 mg (30 mL)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">Tablets, immediate release: regular tablet [Levsin], sublingual [Levsin/SL], dispersible [Anaspaz, ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum daily dose: 0.75 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Drops (Hyosyne [0.125 mg/mL]): 0.125 mg (1 mL) to 0.25 mg (2 mL) every 4 hours or as needed; maximum daily dose: 1.5 mg (12 mL)/<b>da</b>y</p>
<p style="text-indent:-2em;margin-left:8em;">Elixir (Hyosyne [0.125 mg/<b>5 mL</b>]): 0.125 mg (5 mL) to 0.25 mg (10 mL) every 4 hours or as needed; maximum daily dose: 1.5 mg (60 mL)/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">Tablet, dispersible:</p>
<p style="text-indent:-2em;margin-left:10em;">Anaspaz, ED-SPAZ, NuLev: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:10em;">Oscimin: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">Levsin: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:10em;">Oscimin: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">Tablet, sublingual</p>
<p style="text-indent:-2em;margin-left:10em;">Levsin/SL: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:10em;">Oscimin, Symax SL: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Levbid: 0.375 to 0.75 mg every 12 hours; maximum daily dose: 1.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:8em;">Oscimin SR, Symax Duotab, Symax SR: 0.375 to 0.75 mg every 12 hours or 0.375 mg every 8 hours; maximum daily dose: 1.5 mg/<b>day</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7f75083-b721-49f7-927c-43fcfe79b0d9">Preanesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preanesthesia:</b> Children &gt;2 years and Adolescents: IM, IV, SubQ: 5 <b>mcg</b>/kg administered 30 to 60 minutes prior to induction of anesthesia or at the time preoperative opioids or sedatives are administered</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98948cf-89a4-4acd-9a67-a9db2715f5db">Reduce drug-induced bradycardia during surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduce drug-induced bradycardia during surgery:</b> Children &gt;2 years and Adolescents: IV: 0.125 mg; repeat as needed</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58bc67e3-2486-4c5f-afc4-7e2ce32dd93f">Reversal of neuromuscular blockage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of neuromuscular blockage:</b> Children &gt;2 years and Adolescents: IV, IM, SubQ: 0.2 mg for every 1 mg neostigmine (or physostigmine/pyridostigmine equivalent)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51113384"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Dialyzable. There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51113385"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F181182"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Flushing, palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Amnesia (short-term), ataxia, confusion (more common in elderly), dizziness, drowsiness, excitement (more common in elderly), fatigue, hallucination, headache, insomnia, nervousness, psychosis, speech disturbance</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Hypohidrosis, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, ageusia, bloating, constipation, diarrhea, dysgeusia, dysphagia, heartburn, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Decreased lactation, impotence, urinary hesitancy, urinary retention</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision, cycloplegia, increased intraocular pressure, mydriasis</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F181195"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to belladonna alkaloids or any component of the formulation; glaucoma; obstructive uropathy (eg, bladder neck obstruction due to prostatic hypertrophy); myasthenia gravis; obstructive GI tract disease (eg, achalasia, pyloroduodenal stenosis), paralytic ileus, intestinal atony of elderly or debilitated patients, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis; unstable cardiovascular status; myocardial ischemia. <b>Note:</b> Some extended release products are not recommended in children &lt;12 years of age; refer to manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F181179"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effect:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: May be a sign of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy; treatment should be discontinued if this occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral effects: Prolonged use may lead to development of dental caries, periodontal disease, oral candidiasis, or discomfort due to decreased salivation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Has been reported in patients with an extreme sensitivity to anticholinergic effects; usually resolves within 12-48 hours after discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with coronary artery disease, tachyarrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration. Use is contraindicated in patients with unstable cardiovascular status or myocardial ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Use with caution in patients with autonomic neuropathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children with spastic paralysis or brain damage; may be more susceptible to anticholinergic effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878491"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Large doses of anticholinergics may cause a paradoxical reaction in children characterized by hyperexcitability. Oral dosage forms (drops and elixirs) are different (ie, 0.125 mg/mL [drops] and 0.125 mg/5 mL [solution]); precaution should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented with corresponding product formulation. Hyosyne oral drops contain 5% v/v alcohol. Hyosyne oral elixir contains 20% v/v alcohol.</p></div>
<div class="block foc drugH1Div" id="F181189"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Elixir, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyosyne: 0.125 mg/5 mL (473 mL) [contains alcohol, usp; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg/5 mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levsin: 0.5 mg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyosyne: 0.125 mg/mL (15 mL) [lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg/mL (15 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levsin: 0.125 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oscimin: 0.125 mg [peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anaspaz: 0.125 mg [scored; contains corn starch, fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ed-Spaz: 0.125 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NuLev: 0.125 mg [peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symax Duotab: 0.375 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levbid: 0.375 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oscimin SR: 0.375 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symax-SR: 0.375 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.375 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levsin/SL: 0.125 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oscimin: 0.125 mg [peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symax-SL: 0.125 mg [DSC] [mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg</p></div>
<div class="block geq drugH1Div" id="F181175"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F181197"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Elixir</b> (Hyoscyamine Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg/5 mL (per mL): $0.22 - $0.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hyoscyamine Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/mL (per mL): $71.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hyoscyamine Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg/mL (per mL): $2.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Hyoscyamine Sulfate Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $0.56 - $0.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Levsin/SL Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $3.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Hyoscyamine Sulfate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 mg (per each): $0.99 - $1.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Levbid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 mg (per each): $5.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Anaspaz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Hyoscyamine Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $0.57 - $1.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (NuLev Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $2.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Hyoscyamine Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $0.56 - $1.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Levsin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $3.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F181192"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Elixir (Hyosyne): Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat gastrointestinal disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">Drops (Hyosyne): Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat gastrointestinal disorders. Use provided dropper to accurately measure dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, regular release (Levsin, Oscimin): Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat gastrointestinal disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, dispersible: Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat GI disorders.</p>
<p style="text-indent:-2em;margin-left:6em;">Anaspaz: Tablets may be used sublingually, chewed, or swallowed whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Ed-Spaz: Place on top of tongue and allow to dissolve; swallow with saliva.</p>
<p style="text-indent:-2em;margin-left:6em;">NuLev, Oscimin: Tablets may be chewed or placed on tongue and allowed to disintegrate.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, extended release: Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat GI disorders.</p>
<p style="text-indent:-2em;margin-left:6em;">Levbid: Do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Oscimin SR, Symax Duotab, Symax SR: Swallow whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not cut, crush, or chew. Switch to IR tablet, sublingual tablet, or oral solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, sublingual: Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat gastrointestinal disorders.</p>
<p style="text-indent:-2em;margin-left:6em;">Levsin/SL: Tablets may be used sublingually, chewed, or swallowed whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Symax SL: Tablets may be used sublingually or swallowed whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Oscimin: Administer sublingually.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM: </b> May be administered without dilution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Inject over at least 1 minute. May be administered without dilution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SubQ:</b> May be administered without dilution.</p></div>
<div class="block admp drugH1Div" id="F52613008"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administration before meals (~30 to 60 minutes) is recommended but not required when used to treat gastrointestinal disorders. Additional product specific details: </p>
<p style="text-indent:-2em;margin-left:4em;">Drops (Hyosyne): Use provided dropper to accurately measure dose</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, dispersible: </p>
<p style="text-indent:-2em;margin-left:6em;">Anaspaz: Tablets may be used sublingually, chewed, or swallowed whole</p>
<p style="text-indent:-2em;margin-left:6em;">Ed-Spaz: Place on top of tongue and allow to dissolve; swallow with saliva</p>
<p style="text-indent:-2em;margin-left:6em;">NuLev, Oscimin: Tablets may be chewed or placed on tongue and allowed to disintegrate</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, extended release: </p>
<p style="text-indent:-2em;margin-left:6em;">Levbid: Do not crush or chew</p>
<p style="text-indent:-2em;margin-left:6em;">Oscimin SR, Symax Duotab, Symax SR: Swallow whole</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, sublingual: </p>
<p style="text-indent:-2em;margin-left:6em;">Levsin/SL: Tablets may be used sublingually, chewed, or swallowed whole</p>
<p style="text-indent:-2em;margin-left:6em;">Symax SL: Tablets may be used sublingually or swallowed whole</p>
<p style="text-indent:-2em;margin-left:6em;">Oscimin: Administer sublingually</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered undiluted IM, IV, and SubQ. There is no administration rate information provided in the manufacturer's labeling; some centers have administered over at least 1 minute.</p></div>
<div class="block use drugH1Div" id="F181191"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>GI disorders:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Aid in the control of acute episodes of gastric secretion, visceral spasm, hypermotility in spastic colitis, pylorospasm, and associated abdominal cramps; relieve symptoms in functional intestinal disorders (eg, mild dysenteries, diverticulitis) and infant colic.</p>
<p style="text-indent:-2em;margin-left:4em;">Adjunctive therapy for treatment in peptic ulcer; irritable bowel syndrome (IBS) (irritable colon, spastic colon, acute enterocolitis, mucous colitis) and other functional GI disorders; neurogenic bowel disturbances (including splenic flexure syndrome and neurogenic colon).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: The American College of Gastroenterology guideline on the management of IBS recommends against the use of antispasmodics, including hyoscyamine, for treatment of <b>global symptoms</b> of IBS (ACG [Lacy 2021]); however, some experts consider as-needed use beneficial for relief of abdominal pain associated with IBS (Wald 2021).</p></div>
<div class="block mst drugH1Div" id="F181246"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Anaspaz may be confused with Anaprox, Antispas</p>
<p style="text-indent:-2em;margin-left:4em;">Levbid may be confused with Enbrel, Lithobid, Lopid, Lorabid</p>
<p style="text-indent:-2em;margin-left:4em;">Levsin/SL may be confused with Levaquin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Hyoscyamine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299495"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F181184"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Hyoscyamine. Management: Administer immediate release and sublingual oral hyoscyamine before meals, and antacids after meals, when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Hyoscyamine may decrease the serum concentration of Ketoconazole (Systemic).  Management: Take hyoscyamine at least 2 hours after ingestion of ketoconazole. Monitor for decreased therapeutic effects of ketoconazole if used together with hyoscyamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F181198"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. Hyoscyamine crosses the placenta.</p></div>
<div class="block brc drugH1Div" id="F181199"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Hyoscyamine is present in breast milk (trace amounts).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends caution be used if administered to a breastfeeding woman.</p></div>
<div class="block pha drugH1Div" id="F181178"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions, antagonizes histamine and serotonin</p></div>
<div class="block phk drugH1Div" id="F181194"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 2 to 3 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Regular release: 4 to 6 hours; Extended release (Levbid, Symax Duotab): 8 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Regular release: 2 to 3.5 hours; Extended release (Levbid): ~7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038655"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Egacen | Levsin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Spazaway</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Egazil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Duboisine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Hyocimax s</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Neo Allospasmin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Egazil | Egazil duretter</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Eyosin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acupaz | Anapaz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anaspaz | Colidrops | Ed spaz | Hyoscyamine | Hyospaz | Hyosyne | Levbid | Nulev | Oscimin | Spacol t/s | Symax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Levsin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Egazil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Busacon | Buwecon | Levsin | Powecon | Spalytic | Spasmotin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ascher.1">
<a name="Ascher.1"></a>Anaspaz (hyoscyamine sulfate) [prescribing information]. Lenexa, KS: B. F. Ascher &amp; Company Inc; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3382184">
<a name="3382184"></a>Boyson SJ. Bethanechol for Anticholinergic Side Effects. <i>Ann Neurol</i>. 1988;23(4):422-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/3382184/pubmed" id="3382184" target="_blank">3382184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6357938">
<a name="6357938"></a>Cattau EL Jr, Artnak EJ, Castell DO, Meyer GW. Efficacy of atropine as an endoscopic premedication. <i>Gastrointest Endosc</i>. 1983;29(4):285-288. doi:10.1016/s0016-5107(83)72634-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/6357938/pubmed" id="6357938" target="_blank">6357938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Edwards.1">
<a name="Edwards.1"></a>Ed-Spaz [package insert]. Ripley, MS: Edwards Pharmaceutical Inc; May 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Belcher.1">
<a name="Belcher.1"></a>Ed-Spaz tablet (hyoscyamine) [prescribing information]. Largo, FL: Belcher Pharmaceuticals Inc; May 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Hyosine Elixir oral drops and elixir (hyoscyamine) [prescribing information]. Philadelphia, PA: Lannett Company Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586772">
<a name="30586772"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2019;140(8):e382-e482. doi:10.1161/CIR.0000000000000628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/30586772/pubmed" id="30586772" target="_blank">30586772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.1">
<a name="Alaven.1"></a>Levbid (hyoscyamine) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; January 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.2">
<a name="Alaven.2"></a>Levbid tablet (hyoscyamine) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.3">
<a name="Alaven.3"></a>Levsin (hyoscyamine) [prescribing information]. Marietta, GA: Alaven; February 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.4">
<a name="Alaven.4"></a>Levsin injection (hyoscyamine) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; December 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.5">
<a name="Alaven.5"></a>Levsin SL tablet (hyoscyamine) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.6">
<a name="Alaven.6"></a>Levsin tablet (hyoscyamine) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.7">
<a name="Alaven.7"></a>NuLev (hyoscyamine) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; April 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alaven.8">
<a name="Alaven.8"></a>Nulev tablet (hyoscyamine) prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Larken.1">
<a name="Larken.1"></a>Oscimin orally disintegrating tablets (hyoscyamine sulfate) [prescribing information]. Canton, MS: Larken Laboratories Inc; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Larken.2">
<a name="Larken.2"></a>Oscimin sublingual tablets (hyoscyamine sulfate) [prescribing information]. Canton, MS: Larken Laboratories Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Larken.3">
<a name="Larken.3"></a>Oscimin tablets (hyoscyamine sulfate) [prescribing information]. Canton, MS: Larken Laboratories Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Larken.4">
<a name="Larken.4"></a>Oscimin tablets (hyoscyamine) prescribing information]. Canton, MS: Larken Laboratories Inc; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Larken.5">
<a name="Larken.5"></a>Oscimin-SR (hyoscyamine sulfate) [prescribing information]. Canton, MS: Larken Laboratories Inc; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-382907">
<a name="382907"></a>Shutt LE, Bowes JB. Atropine and Hyoscine. <i>Anaesthesia</i>. 1979;34(5):476-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyoscyamine-drug-information/abstract-text/382907/pubmed" id="382907" target="_blank">382907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capellon.1">
<a name="Capellon.1"></a>Symax Duotab (hyoscyamine sulfate) [prescribing information]. Fort Worth, TX: Capellon Pharmaceuticals LLC; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capellon.2">
<a name="Capellon.2"></a>Symtax Duotab tablets (hyoscyamine) prescribing information]. Ft. Worth, TX: Capellon Pharmaceuticals LLC; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capellon.3">
<a name="Capellon.3"></a>Symax-SL (hyoscyamine sulfate) [prescribing information]. Fort Worth, TX: Capellon Pharmaceuticals LLC; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capellon.4">
<a name="Capellon.4"></a>Symax-SR (hyoscyamine sulfate) [prescribing information]. Fort Worth, TX: Capellon Pharmaceuticals LLC; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capellon.5">
<a name="Capellon.5"></a>Symtax SR tablet (hyoscyamine) prescribing information]. Ft. Worth, TX: Capellon Pharmaceuticals LLC; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 3, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8545 Version 411.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
